Related Experiment Video

Updated: Aug 23, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Candesartan for the treatment of hypertension and heart failure

Jan Ostergren1

  • 1Karolinska University Hospital, Department of Medicine, Solna, 171 76 Stockholm, Sweden. jan.ostergren@kus.se

Expert Opinion on Pharmacotherapy
|June 24, 2004
PubMed

Insights

Candesartan, an angiotensin II receptor blocker, effectively treats hypertension and heart failure. It offers significant benefits for patients intolerant to ACE inhibitors and reduces cardiovascular events when added to ACE inhibitors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker.
  • It is an effective, long-acting antihypertensive agent with a favorable side effect profile.
  • Emerging evidence suggests potential benefits in diabetes prevention.

Purpose of the Study:

  • To evaluate the clinical value of candesartan in a broad spectrum of heart failure patients.
  • To assess the efficacy of candesartan in patients unable to tolerate angiotensin-converting enzyme inhibitors (ACEIs).
  • To determine the added benefit of candesartan when combined with ACEIs and its effect on heart failure hospitalization in preserved systolic function.

Main Methods:

  • The CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) programme comprised three prospective randomized outcome trials.
  • Trials included patients with symptomatic heart failure, regardless of background therapy and ventricular function.
  • Specific analyses focused on patients intolerant to ACEIs, addition of candesartan to ACEIs, and patients with preserved systolic function.

Main Results:

  • Candesartan demonstrated clinical value across a wide range of symptomatic heart failure patients.
  • Significant benefits were observed in patients intolerant to ACEIs, comparable to ACEI therapy.
  • Adding candesartan to ACEIs (CHARM-Added) further reduced symptoms, morbidity, and cardiovascular mortality.
  • Candesartan reduced heart failure hospital admissions in patients with preserved systolic function (CHARM-Preserved).

Conclusions:

  • Candesartan is a valuable therapeutic option for symptomatic heart failure patients.
  • It provides significant benefits for patients intolerant to ACEIs and enhances outcomes when added to ACEI therapy.
  • Candesartan effectively reduces heart failure hospitalizations in patients with preserved systolic function.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...